Management of Chemotherapy Induced Cardiomyopathy
نویسندگان
چکیده
منابع مشابه
Management of Chemotherapy Induced Cardiomyopathy
Chemotherapy related cardiac dysfunction (CRCD) is a serious complication of anticancer therapy. CRCD can be classified into two types. Type I CRCD is exemplified by anthracyline- induced cardiac dysfunction and type II CRCD is exemplified by trastuzumab- induced cardiac dysfunction. The mechanism of cardiac toxicity in both types is not well defined. Certain risk factors may play a role in dev...
متن کاملChemotherapy Induced Cardiomyopathy: Pathogenesis, Monitoring and Management
UNLABELLED The survival rate of cancer patients has greatly increased over the last 20 years. However, to achieve this result, a considerable price has been paid in terms of the side effects associated with the intensive anticancer treatment. The most common adverse effect is cardiotoxicity which may compromise the clinical effectiveness of chemotherapy, affecting the patient's survival and qua...
متن کاملChemotherapy-Induced Cardiomyopathy in Breast Cancer Patients
Published by Kowsar. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The globally increasing incidence of cancer and its associated mortality has become a main challenge for humankind. This problem is more serious in ...
متن کاملINTERFERON INDUCED CARDIOMYOPATHY: CASE REPORTS
There are few reports concerning interferon induced myocardial dysfunction. A known case of multiple myeloma who was receiving interferon alpha (IFA) for 14 months was brought to the emergency room in frank: pulmonary edema. After treatment of heart failure and discontinuation of interferon alpha, he remained asymptomatic thereafter. Another case of chronic active hepatitis on IFA complain...
متن کاملManagement of chemotherapy induced emesis
Important progress has been achieved in the last few years in the prevention of chemotherapy-induced nausea and vomiting thanks to the introduction in clinical practice first of the 5-HT3 antagonists and of the NK1 antagonists more recently. To prevent acute emesis induced by cisplatin/moderately emetogenic chemotherapy, a combination of aprepitant plus a 5-HT3 antagonist and dexamethasone/a 5-...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Current Cardiology Reviews
سال: 2012
ISSN: 1573-403X
DOI: 10.2174/157340311799960681